Skip to main content
SpringerLink
Log in

Tumor immunology, immune surveillance and immunotherapy of head and neck squamous carcinoma

  • Chapter
Head and Neck Oncology

Part of the book series: Cancer Treatment and Research ((CTAR,volume 22))

Abstract

Overall survival rates for patients with advanced head and neck cancer remain dismal despite intensive combined modality treatment approches using surgery, radiation therapy and chemotherapy. It is well established that single modality treatment strategies employing surgery or radiation therapy for small, locally confined tumors achieve 5-year survival rates of 70–90%. However, in patients with extensive primary tumors or regional metastases, the 5-year survival rates range from 0–60%. These generally poor results have not been significantly improved by intensive combinations of surgery and radiation. This has been attributed to failures in the control or prevention of distant metastases despite occasional reductions in local recurrence rates and prolongation of disease free interval.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Tarpley JL, Potvin C, Chretien PB: Prolonged depression of cellular immunity in cured laryngopharyngeal cancer patients treated with radiation therapy. Cancer 35: 638–644, 1975.

    Article  PubMed  CAS  Google Scholar 

  2. Prehn R, Main D: Immunity to methylcholanthrene induced sarcoma. J Natl Cancer Inst 18: 768–778, 1957.

    Google Scholar 

  3. Hellstrom I: A colony inhibition (CI) technique for demonstration of tumor cell destruction by lymphoid cells in in vitro. Int J Cancer 2: 65–69, 1967.

    Article  PubMed  CAS  Google Scholar 

  4. Hellstrom I, Hellstrom KE, Sjogren HO, Warner GA: Demonstration of cell-mediated immunity to human neoplasms of various histologic types. Int J Cancer 7: 1–16, 1971.

    Article  PubMed  CAS  Google Scholar 

  5. McCoy JL, Jerome LF, Dean JH, et al: Inhibition of leukocyte migration by tumor- associated antigens in soluable extracts of human breast carcinoma. J Natl Cancer Inst 53: 11–17, 1974.

    PubMed  CAS  Google Scholar 

  6. Halliday WJ, Koppi TA, Khan JM, Davis NC: Leukocyte adherence inhibition. Tumor specificity of cellular serum-blocking reactions in human melanoma, breast cancer, and colorectal cancer. J Natl Cancer Inst 65: 327–335, 1980.

    PubMed  CAS  Google Scholar 

  7. Yonomoto RH, Fujisawa T, Waldman SR: Effect of serum blocking factors on leukocyte adherence inhibition in breast cancer patients: specificity and correlation with tumor burden. Cancer 41: 1289–1297, 1978.

    Article  Google Scholar 

  8. McCoy JL, Jerome LF, Cannon GB, et al: Reactivity of lung cancer patients in leukocyte migration inhibition assays to 3-M potassium chloride extracts of fresh tumor and tissue- cultered cells derived from lung cancer. J Natl Cancer Inst 59: 1414–1418, 1977.

    Google Scholar 

  9. Goldrosen MH, Russo AJ, Howell JH, et al: Evaluation of mico-leukocyte adherence inhibition as an immunodiagnostic test for pancreatic cancer. Cancer Res 29: 633–637, 1978.

    Google Scholar 

  10. McCoy JL, Jerome LF, Dean JH, et al: Inhibition of leukocyte migration by tumor- associated antigens in soluable extracts of human malignant melanoma. J Natl Cancer Inst 55: 19–24, 1975.

    PubMed  CAS  Google Scholar 

  11. Roth J A, Wesley RA: Human tumor-associated antigens detected by serological technique: analysis of autologous humoral immune responses to primary and metastatic human sarcomas by an enzyme-linked immunoabsorbent solid–phase assay. Cancer Res 42: 3978–3986, 1982.

    PubMed  CAS  Google Scholar 

  12. Ueda R, Shiku H, Pfreundschuh M, et al: Cell surface antigens of human renal cancer defined by autologous typing. J Exp Med 150: 564–579, 1979.

    Article  PubMed  CAS  Google Scholar 

  13. Carey TE, Kimmel KA, Schwartz DR, et al: Antibodies to human squamous cell carcinoma. Otolaryngology Head Neck Surg 91: 482–491, 1983.

    CAS  Google Scholar 

  14. Sofen H, O’Toole C: Anti–squamous tumor antibodies in patients with squamous cell carcinoma. Cancer Res 38: 199–203, 1978.

    PubMed  CAS  Google Scholar 

  15. Adelstein EH, Davis WE, Oxenhandler RW, et al: Lymphocyte-tumor cell interaction in patients with and neck cancer: Laryngoscope 88: 575–581, 1978.

    PubMed  CAS  Google Scholar 

  16. Ariyan S, Krizek TJ, Mitchell MS: Identification of squamous cell carcinoma of the head and neck by tissue culture and immunological testing. Plast Recon Surg 59: 386–394, 1977.

    Article  CAS  Google Scholar 

  17. Aust JC, Rabuzzi D, Reed G: Tissue-cultured head and neck tumors: their use in in vitro assays of immune response. Trans Am Aced Ophth Otol 84: 603–608, 1977.

    Google Scholar 

  18. Kennedy JT: A search for common tumor specific antigen and serum blocking factor in head and neck epidermoid carcinoma. Laryngoscope 85: 806–822, 1975.

    Article  PubMed  CAS  Google Scholar 

  19. Krause CJ, Nysather J, McCabe BF: Characterization of tumor antigen in epidermoid carcinoma. Ann Otol 84: 787–792, 1975.

    CAS  Google Scholar 

  20. Ibrahim AN, Robinson RA, Marr L, et al: Tumor–associated antigens in cervical cancer tissues and in sera from patients with cervical cancer or with head and neck cancer. J Natl Cancer Inst 63: 319–323, 1979.

    PubMed  CAS  Google Scholar 

  21. Klein G, Sjogren HO, Klein E, Hellstrom KE: Demonstration of resistance against methyl- cholanthrene-induced sarcomas in the primary autochthonous host. Cancer Res 20:1561–1572, 1960.

    Google Scholar 

  22. Hellstrom I, Sjogren HO: In vitro demonstration of humoral and cell-bound immunity against common specific transplantation antigens of adenovirus 12-induced mouse and hamster tumors. J Exp Med 125: 1105–1118, 1967.

    Article  PubMed  CAS  Google Scholar 

  23. Gorczyncki RM: Evidence for in vivo protection against murine sarcoma virus-induced tumors by T lymphocytes from immune animals. J Immunol 112: 533, 1974.

    Google Scholar 

  24. Law LW: Studies of the significance of tumor antigens in induction and repression of neoplastic disease: presidential address. Cancer Res 29: 1, 1969.

    PubMed  CAS  Google Scholar 

  25. Fisher MS, Kripke ML: Further studies on the tumor-specific suppressor cells induced by ultraviolet radiation. J Immunol 121: 1139–1144, 1978.

    PubMed  CAS  Google Scholar 

  26. Hellstrom I, Hellstrom KE: Cell-mediated reactivity to human tumor-type associated antigens: Does it exist? J Biol Resp Mod 2: 310–320, 1983.

    CAS  Google Scholar 

  27. Rosenberg EB, McCoy JL, Green SS, et al: Destruction of human lymphoid tissue culture cell lines by human peripheral lymphocyte in 51CR-release cellular cytotoxicity assays. J Natl Cancer Inst 52: 345, 1974.

    PubMed  CAS  Google Scholar 

  28. Riesenfeld I, Orn A, Gidlund M, et al: Positive correlation between in vitro NK activity and in vivo resistance towards AKR lymphoma cells. Int J Cancer 25: 399, 1980.

    Article  PubMed  CAS  Google Scholar 

  29. Becker S, Klein E: Decreased ‘natural killer’ effect in tumor bearing mice and its relation to the immunity against oncorna virus-determined cell surface antigens. Eur J Immunol 6: 892, 1976.

    Article  Google Scholar 

  30. Karre K, Klein GO, Kiessling R, et al: Low natural in vivo resistance to syngeneic leu- kemias in natural killer deficient mice. Nature 284: 624, 1980.

    Article  PubMed  CAS  Google Scholar 

  31. Dent PB, Fish LA, White WF, Good RA: Chediak-Higashi syndrome: observations on the nature of the associated malignancy. Lab Invest 15: 1634, 1966.

    PubMed  CAS  Google Scholar 

  32. North RJ: The concept of the activated macrophage. J Immunol 121: 806–809, 1978.

    PubMed  CAS  Google Scholar 

  33. Goodwin JS, Webb DR: Regulation of the immune response by prostaglandins. Clin Immunol Immunopath 15: 106–122, 1980.

    Article  CAS  Google Scholar 

  34. Holden HT, Haskill JS, Kirchner H, Herberman RB: Two functionally distinct anti–tumor effector cells isolated from primary murine sarcoma virus-induced tumors. J Immunol 117: 440, 1976.

    PubMed  CAS  Google Scholar 

  35. Gillespie GY, Hansen CB, Hoskins RG, Russell SW: Inflammation cells in solid murine neoplasms. IV. Cytolytic T lymphocytes isolated from regressing or progressing Moloney sarcomas. J Immunol 119: 564, 1977.

    PubMed  CAS  Google Scholar 

  36. Russell SW, Mcintosh AT: Macrophages isolated from regressing Moloney sarcomas are more cytotoxic than those recovered from progressing sarcomas. Nature 268: 69, 1977.

    Article  PubMed  CAS  Google Scholar 

  37. Jondal M, Svedmyr E, Klein E, Singh S: Killer T-cells in a Burkitt’s lymphoma biopsy. Nature 255: 405, 1975.

    Article  PubMed  CAS  Google Scholar 

  38. The TH, Eibergen R, Lamberts HB, et al: Immune phagocytosis in vivo of human malignant melanoma cells. Acta Med Scand 192: 141, 1972.

    Article  PubMed  CAS  Google Scholar 

  39. Vose BM, Moore ML: Suppressor cell activity of lymphocytes infiltrating human lung and breast tumors. Int J Cancer 24: 579, 1979.

    Article  PubMed  CAS  Google Scholar 

  40. Houck JF, McCormick KJ, Panje WR, et al: Modulation of mitogenic response by cells from regional lymph nodes of head and neck cancer patients. Proc Am Assoc Cancer Res 24: 202, 1983.

    Google Scholar 

  41. Yu A, Watts H, Jaffe N, Parkman R: Concomitant presence of tumor specific cytotoxic and inhibitor lymphocytes in patients with osteogenic sarcoma. N Engl J Med 297: 121, 1977.

    Article  PubMed  CAS  Google Scholar 

  42. Uchida A, Micksche M: Suppressor cells for natural killer activity in carcinomatous pleural effusions of cancer patients. Cancer Immunol Immunother 11: 255, 1981.

    Google Scholar 

  43. Fidler U, Hart IR: Biologic diversity in metastatic neoplasms: origins and implications. Science 217: 998, 1982.

    Article  PubMed  CAS  Google Scholar 

  44. Fidler U, Kripke ML: Tumor cell antigenicity, host immunity and cancer metastasis. Cancer Immunol Immunother 7: 201–205, 1980.

    Article  Google Scholar 

  45. Fidler IJ, Gersten DM, Kripke ML: The influence of immune status on the metastases of three murine fiborsarcomas of different immunogenicities. Cancer Res 39: 3816, 1979.

    PubMed  CAS  Google Scholar 

  46. Fidler IJ, Gersten DM, Hart IR: The biology of cancer invasion and metastasis. Adv Cancer Res 28: 149, 1978.

    Article  PubMed  CAS  Google Scholar 

  47. Cole WH: Spontaneous regression of cancer and the importance of finding its cause. Natl Cancer Inst Monogr 44: 5–9, 1976.

    PubMed  CAS  Google Scholar 

  48. Baker RR: Spontaneous regression of bronchogenic carcinoma. Natl Cancer Inst Monogr 44: 31–33, 1976.

    PubMed  CAS  Google Scholar 

  49. Ruckdeschel JC, et al.: Postoperative empyema improves survival in lung cancer: documentation and analysis of a natural experiment. N Engl J Med 287: 1013–1017, 1972.

    Article  PubMed  CAS  Google Scholar 

  50. Schantz SP, Skolnik EM, O’Neill JV: Improved survival associated with postoperative wound infection in laryngeal cancer: an analysis of its therapeutic implications. (Abstract), Research Forum, American Academy of Otolaryngology, October 1979.

    Google Scholar 

  51. Harris JP, Penn I: Immunosuppression and the development of malignancies of the upper airway and related structures. Laryngoscope 91: 520–528, 1981.

    Article  PubMed  CAS  Google Scholar 

  52. Good RA, Finstad J: Essential relationship between the lymphoid system, immunity and malignancy. Natl Cancer Inst Monogr 31: 41–58, 1969.

    PubMed  CAS  Google Scholar 

  53. Kennedy AW, Hart WR: Multiple squamous-cell carcinomas in Fanconi’s anemia. Cancer 50: 811–814, 1982.

    Article  PubMed  CAS  Google Scholar 

  54. Reed K, Ravikumar TS, Gifford RRM, Grage TB: The association of Fanconi’s anemia and squamous cell carcinoma. Cancer 52: 926–928, 1983.

    Article  PubMed  CAS  Google Scholar 

  55. Birkeland SA: Malignant tumors in renal transplant patients. Cancer 51: 1571–1575, 1983.

    Article  PubMed  CAS  Google Scholar 

  56. Burbank F: Patterns in cancer mortality in the United States: 1950–1967. Natl Cancer Inst Monogr 33: 1–594, 1972.

    Google Scholar 

  57. Henry L: Involution of the human thymus. J Path Bact 93: 661, 1967.

    Article  PubMed  CAS  Google Scholar 

  58. Weksler ME, Hutteroth TH: Impaired lymphocyte function in aged humans. J Clin Invest 53: 99–104, 1974.

    Article  PubMed  CAS  Google Scholar 

  59. Carosella ED, Mochanko K, Braun M: Rosette forming T cells in human peripheral blood at different ages. Cell Immunol 12: 323–325, 1974.

    Article  PubMed  CAS  Google Scholar 

  60. Waldorf DS, Willkens RF, Decker JL: Impaired delayed hypersensitivity in an aging population. J Am Med Assoc 203: 111, 1968.

    Article  Google Scholar 

  61. Bach JF, Papiernick M, Lavasseur P, et al.: Evidence for a serum-factor secreted by the human thymus. Lancet 2: 1056–1058, 1972.

    Article  PubMed  CAS  Google Scholar 

  62. McClure JE, Lameris N, Wara DM, Goldstein AL: Immunochemical studies on thymosin: radioimmunoassay of thymosin a1. J Immunol 128: 368–375, 1981.

    Google Scholar 

  63. Wolf GT, Chretien PB, Weiss JF, et al.: Effects of smoking and age on serum levels of immune reactive proteins. Otolaryngol Head Neck Surg 90: 319–326, 1982.

    PubMed  CAS  Google Scholar 

  64. Hersh EM, Whitecare JP, McCredie KB, et al.: Chemotherapy, immunocompetence, immunosuppression and prognosis in acute leukemia. N Engl J Med 285: 1211–1216, 1971.

    Article  PubMed  CAS  Google Scholar 

  65. Leventhal BG, Halterman RH, Rosenberg EB, Herberman RB: Immune reactivity of leukemia patients to autologous blast cells. Cancer Res 32: 1820–1825, 1972.

    PubMed  CAS  Google Scholar 

  66. Sokal JE, Aungst CW: Cellular responses and prognosis in malignant lymphomas. Natl Cancer Inst Monogr 34: 109–112, 1971.

    PubMed  CAS  Google Scholar 

  67. Eilber FR, Morton DL: Impaired immunologic reactivity and recurrence following cancer surgery, Cancer 25: 362–367, 1970.

    Article  PubMed  CAS  Google Scholar 

  68. Israel L, Mugica J, Chahinian P: Prognosis of early bronchogenic carcinoma. Survival cures of 451 patients after resection of lung cancer in relation to the results of pre-operative tuberculin skin tests. Biomedicine 19: 68–72, 1973.

    PubMed  CAS  Google Scholar 

  69. Pinsky CM, Wanebo HJ, Mike V, et al.: Delayed cutaneous hypersensitivity reactions and prognosis in patients with cancer. Ann NY Acad Sci 276: 407–410, 1976.

    Article  PubMed  CAS  Google Scholar 

  70. Maisel RH, Ogura JH, Dinitrochlorobenzene skin sensitization and peripheral lymphocyte count: predictors of survival in head and neck cancer. Ann Otol Rhinol Laryngol 85:517–522, 1976.

    Google Scholar 

  71. Hilal EY, Wanebo HJ, Pinsky CM, et al.: Immunological evaluation and prognosis in patients with head and neck cancer. Am J Surg 134: 469–473, 1977.

    Article  Google Scholar 

  72. Mandel MA: Skin testing for prognosis or therapy formulation in cancer patients: caveat emptor. Plast reconstr Surg 57: 64–66, 1976.

    Google Scholar 

  73. Bosworth JL, Thaler S, Ghossein NA: Delayed hypersensitivity and local control of patients treated by radiotherapy for head and neck cancer. Am J Surg 132: 46–48, 1976.

    Article  PubMed  CAS  Google Scholar 

  74. Stefani S, Kerman R, Abbate J: Serial studies of immunocompetence in head and neck cancer patients undergoing radiation therapy. Am J Roentgenol Radium Ther Nucl Med 126: 880–886, 1976.

    Google Scholar 

  75. Rayn RE, Neel HB: Correlation of preoperative immunologic test results with recurrence in patients with head and neck cancer. Otolaryngol Head Neck Surg 88: 58–63, 1980.

    Google Scholar 

  76. Jenkins VK, Griffiths CM, Ray P, et al.: Radiotherapy and head and neck cancer. Role of lymphocyte response and clinical stage. Arch Otolaryngol 106: 414–418, 1980.

    PubMed  CAS  Google Scholar 

  77. Eastham RJ, Mason JM, Jennings BR, et al: T-cell rosette test in squamous cell carcinoma. Arch Otolaryngol 102: 171–175, 1976.

    PubMed  CAS  Google Scholar 

  78. Catalona WJ, Sample WF, Chretien PB: Lymphocyte reactivity in cancer patients: correlation with tumor histology and clinical stage. Cancer 31: 65–71, 1973.

    Article  PubMed  CAS  Google Scholar 

  79. Mason JM, Kitchens GG, Eastham RJ, Jennings BR: T-lymphocytes and survival of head and neck squamous cell carcinoma. Arch Otolaryngol 103: 223–227, 1977.

    PubMed  CAS  Google Scholar 

  80. Ehrlich P: Uber den jetzigen Stand der Karzinoforschung. In: Himmelweit H (ed) The Collected Papers of Paul Ehrlich, Vol 11. London, Pergamon, 1957, p550.

    Google Scholar 

  81. Burnett MF: Immunological surveillance in neoplasia. Transplant Rev 7: 3–25, 1971.

    Google Scholar 

  82. Rygaard J, Povlsen CO: The nude mouse vs. the hypothesis of immunological surveillance. Transplant Rev 28: 42, 1976.

    Google Scholar 

  83. Deegan MJ, Coulthard SW: Spontaneous rosette formation and rosette inhibition assays in patients with squamous cell carcinoma of the head and neck. Cancer 39: 2137–2141, 1977.

    Article  PubMed  CAS  Google Scholar 

  84. Olkowski ZL, Wilkins SA: T-lymphocyte levels in the peripheral blood of patients with cancer of the head and neck. Am J Surg 130: 440–444, 1975.

    Article  PubMed  CAS  Google Scholar 

  85. Deegan MJ, Coulthard SW, Qualman SJ, Schork MA: A correlative analysis of in vitro parameters of cellular immunity in patients with squamous cell carcinoma of the head and neck. Cancer Res 37: 4475–4481, 1977.

    PubMed  CAS  Google Scholar 

  86. Wanebo HJ, Jun MX, Strong EW, et al: T-cell deficiency in patients with squamous cell carcinoma of the head and neck. Am J Surg 130: 445–451, 1975.

    Article  PubMed  CAS  Google Scholar 

  87. Zighelboim J, Dorey F, Parker NH, et al: Immunologic evaluation of patients with advanced head and neck cancer receiving weekly chemoimmunotherapy. Cancer 44:117–123, 1979.

    Article  PubMed  CAS  Google Scholar 

  88. Chretien PB: Unique immunobiological aspects of head and neck squamous carcinoma. Can J Otolaryngol 4: 225–235, 1975.

    PubMed  CAS  Google Scholar 

  89. Allison AC: Interactions of antibodies, complement components and various cell types in immunity against viruses and pyogenic bacteria. Transplant Rev 19: 3, 1974.

    PubMed  CAS  Google Scholar 

  90. Hollingshead AC, Lee O, Chretien PB, et al: Antibodies to herpes virus nonvirion antigens in squamous carcinoma. Science 182: 713–715, 1973.

    Article  Google Scholar 

  91. Shillitoe EJ, Greenspan D, Greenspan JS, et al: Neutralizing antibody to herpes simplex virus type1 in patients with oral cancer. Cancer 49: 2315–2320, 1982.

    Article  PubMed  CAS  Google Scholar 

  92. Sheinin R: Viruses: Causative agents of cancer. Laryngoscope 185: 468–486, 1975.

    Article  Google Scholar 

  93. Smith HG, Chretien PB, Henson DE, et al: Viral-specific humoral immunity to herpes simplex–induced antigens in patients with squamous carcinoma of the head and neck. Am J Surg 132: 541–548, 1976.

    Article  PubMed  CAS  Google Scholar 

  94. Arneborn P, Biberfeld G: T-lymphocyte subpopulations in relation to immunosuppression in measles and varicella. Infection and Immunity 29: 29–37, 1983.

    Google Scholar 

  95. Waele MD, Thielmans C, VanCamp BKG: Chracterization of immunoregulatory T cells in EBV–induced infectious mononucleosis by monoclonal antibodies. N Engl J Med 304:460–462, 1981.

    Google Scholar 

  96. Carney WP, Rubin RH, Hoffman RA, et al:Analysis of T-lymphocyte subsets in cytomegalovirus mononucleosis. J Immunol 126: 2114–2116, 1981.

    PubMed  CAS  Google Scholar 

  97. Kripke ML: Immunobiology of photocarcinogenesis. In: Parrish JA (ed) The Effect of Ultraviolet Radiation on the Immune System. Johnson and Johnson, 1983, pp 87–100.

    Google Scholar 

  98. Yata J, Shimbo T, Sawaki S: Changes in T-cell subsets and their clinical significance in cancer patients. In: De-The G, Ito Y (eds) Nasopharyngeal Carcinoma: Etiology and Control. Lyon, IARC Scientific Publication No. 20, 1978, pp 511–521.

    Google Scholar 

  99. Vena GA, Angelini G, D’Ovidio R, et al: Cell–mediated immunity in squamous cell and basal cell carcinomas. G Ital Dermatol Venereol 117: 263–267, 1982.

    PubMed  CAS  Google Scholar 

  100. Vena GA, Angelini G, D’Ovidio R, et al: T-lymphocytes with Fc–IgG receptors in skin cancers. Acta Dermatovener (Stockholm) 61: 555–577, 1981.

    CAS  Google Scholar 

  101. Balaram P, Vasudeven DM: Quantitation of Fc receptor-bearing T-lymphocytes (TG and Tm) in oral cancer. Cancer 52: 1837–1840, 1983.

    Article  PubMed  CAS  Google Scholar 

  102. Saxon A, Portis J: Lymphoid subpopulation changes in regional lymph nodes in squamous head and neck cancer. Cancer Res 37: 1154–1158, 1977.

    PubMed  CAS  Google Scholar 

  103. Camacho ES, Schecter P, Graham R, Camacho SA: Immune competence evaluation including T-cell subsets in patients with lung or head and neck carcinomas and smokers. Proc Am Soc Clin Oncol 1: 40, 1982.

    Google Scholar 

  104. Johnson JT, Rabin BS, Hersch B, Tharel PB: T-lymphocyte subpopulations in head and neck carcinoma. ( Accepted for publication ), Otolaryngol Head Neck Surg, June 1983.

    Google Scholar 

  105. Reinherz EL, Moretta L, Roper M, et al: Human lymphocyte subpopulations defined by Fc receptors and monoclonal antibodies. J Exp Med 151: 969–974, 1980.

    Article  PubMed  CAS  Google Scholar 

  106. Wolf GT, Lovett EF, McClatchey K, et al: Impaired lymphokine production in patients with head and neck cancer correlates with alterations in lymphocyte subpopulations. (unpublished).

    Google Scholar 

  107. Lipscomb H, Jacobs AJ, Bechtold T, et al: Lymphocyte subpopulations in patients with cervical carcinoma. (Abstract), Eleventh Midwest Autumn Immunology Conference Workshops, Chicago. Illinois, November 1, 1982.

    Google Scholar 

  108. Moller G, Moller E: Immunological surveillance against neoplasia. In: Castro JE (eds) Immunologic Aspects of Cancer. Baltimore, University Park Press, 1978, p206.

    Google Scholar 

  109. Gatenby PA, Basten A, Creswick P: ‘Sneaking through’, a T-cell dependent phenomenon. Br J Cancer 44: 753, 1981.

    Article  PubMed  CAS  Google Scholar 

  110. Broder S, Waldmann TA: The suppressor–cell network in cancer. New Engl J Med 299: 1335–1341, 1978.

    Article  PubMed  CAS  Google Scholar 

  111. Kapp JA, Pierce CW, Theze J, Benacerraf B: Modulation of immune responses by suppressor T cells. Fed Proc 37: 2361–2364, 1978.

    PubMed  CAS  Google Scholar 

  112. Hersh EM, Patt YZ, Murphy SG, et al: Radiosensitive, thymic hormone sensitive peripheral blood suppressor cell activity in cancer patients. Cancer Res 40: 3134–3140, 1980.

    PubMed  CAS  Google Scholar 

  113. Hart IR, Fidler IJ: The implications of tumor heterogeneity for studies on the biology and therapy of cancer metastases. Biochem Biophys Acta 651: 37–50, 1981.

    PubMed  CAS  Google Scholar 

  114. Poste G: Experimental systems for analysis of the malignant phenotype. Cancer Metastasis Rev 1: 141–199, 1982.

    Article  PubMed  CAS  Google Scholar 

  115. Kripke ML, Gruys E, Fidler U: Metastatic heterogeneity of cells from an ultraviolet light- induced murine fibrosarcoma of recent origin. Cancer Res 38: 2962–2967, 1978.

    PubMed  CAS  Google Scholar 

  116. Fidler IJ, Kripke ML: Metastasis results from pre–existing variant cells within a malignant tumor. Science 197: 893–895, 1977.

    Article  PubMed  CAS  Google Scholar 

  117. Gooding LR: Characterization of a progressive tumor from C3H fibroblasts transformed in vitro with SV-40 virus: immunoresistance in vivo correlates with phenotypic loss of H-2K. J Immunol 129: 1306, 1982.

    PubMed  CAS  Google Scholar 

  118. Urban JL, Burton RC, Holland JM, et al.: Mechanisms of syngeneic tumor rejection, susceptibility of host-selected progressor variants to various immunological effector cells. J Exp Med 155: 557, 1982.

    Article  PubMed  CAS  Google Scholar 

  119. Timonen T, Ortaldo JR, Herberman RB: Characterization of human large granular lymphocytes and the relationship to natural killer and K cells. J Exp Med 153: 569–582, 1981.

    Article  PubMed  CAS  Google Scholar 

  120. Landazuri MO, Silva A, Alvarez J, Herberman RB: Evidence that natural cytotoxic and antibody dependent cellular cytoxicity are mediated in humans by the same effector cell populations. J Immunol 123: 252–258, 1979.

    PubMed  Google Scholar 

  121. Lanier LL, Le AM, Phillips JH: Subpopulations of human natural killer cells defined by expression of the Leu-7 (HNK-1) and Leu-11 (NK-15) antigens. J Immunol 131:1789–1796, 1983.

    Google Scholar 

  122. West WH, Boozer RB, Herberman RB: Low affinity E-rosette formation by the human K cell. J Immunol 120: 90, 1978.

    PubMed  CAS  Google Scholar 

  123. Kay HD, Horwitz DA: Evidence by reactivity with hybridoma antibodies for a probable myeloid origin of peripheral blood cells active in natural cytotoxicity and antibody-dependent cell-mediated cytotoxicity. J Clin Invest 66: 847, 1980.

    Article  PubMed  CAS  Google Scholar 

  124. Ortaldo JR, Sharrow SO, Timonen T, Herberman RBb: Determination of surface antigens on highly purified human NK cells by flow cytometry with monoclonal antibodies. J Immunol 127: 2401, 1981.

    PubMed  CAS  Google Scholar 

  125. Stutman O: Delayed tumor appearance and absence of regression in nude mice infected with murine sarcoma virus. Nature 253: 142, 1975.

    Article  PubMed  CAS  Google Scholar 

  126. Roder JC, Halistes T: Do NK cells play a role in anti-tumor surveillance? Immunol Today 1: 96, 1980.

    Article  Google Scholar 

  127. Habu S, Fukui H, Shimamura K, Kasai M, et al.: In vivo effects of anti-asialo GMI, reduction of NK activity and enhancement of transplanted tumor growth in nude mice. J Immunol 127: 34–36, 1981.

    PubMed  CAS  Google Scholar 

  128. Talmadge JE, Meyers KM, Prieur DJ, Starkey JR: Role of NK cells in tumor growth and metastasis in beige mice. Nature 284: 622–624, 1980.

    Article  PubMed  CAS  Google Scholar 

  129. Hanna N: Role of natural killer cells in control of cancer metastases. Cancer Metastasis Rev 1: 45, 1982.

    Article  PubMed  CAS  Google Scholar 

  130. Balch CM, Tilden AB, Dougherty PA, Cloud G, Abo T: Depressed levels of granular lymphocyte with natural killer cell function in 247 cancer patients. Proc Am Assoc Cancer Res 23: 905, 1983.

    Google Scholar 

  131. Ching CY, Hokama Y, Jim E, et al.: Evaluation of natural killer function and interferon in vitro in patients with selected malignancies. Proc Am Assoc Cancer Res 23: 909, 1983.

    Google Scholar 

  132. Tilden AB, Abo T, Balch CM: Suppressor cell function of human granular lymphocytes identified by the HNK-1 (Leu 7) monoclonal antibody. J Immunol 130: 1171–1175, 1983.

    PubMed  CAS  Google Scholar 

  133. Gorelik E, Wiltrout R, Okumura K, et al.: Acceleration of metastatic growth in anti-asialo GM-1-treated mice. In: Herberman RB (ed) NK Cells and Other Natural Effector Cells. New York, Academic Press, 1982, pp 1331–1337.

    Google Scholar 

  134. Hanna N, Fidler IJ: Relationship between metastatic potential and resistance to natural killer cell-mediated cytotoxicity in three murine tumor systems. J Natl Cancer Inst 66: 1183–1190, 1981.

    Google Scholar 

  135. Brodt P, Lala PK: Changes in T cell subsets in mice during the growth of spontaneous mammary tumors. Proc Am Assoc Cancer Res 23: 236, 1983.

    Google Scholar 

  136. Buessow SC, Paul RD, Lopez DM: The isolation and characterization of lymphocytes infiltrating a mammary adenocarcinoma. Proc Am Assoc Cancer Res 23: 238, 1983.

    Google Scholar 

  137. Flannery GR, Robins RA, Baldwin RW: Natural killer cells infiltrate chemically induced sarcoma. Cell Immunol 61: 1–10, 1981.

    Article  PubMed  CAS  Google Scholar 

  138. Hersey P, Hobbs A, Edwards A, et al: Relationship between natural killer cell activity and histological features of lymphocyte infiltration and partial regression of the primary tumor in melanoma patients. Cancer Res 42: 363–368, 1982.

    PubMed  CAS  Google Scholar 

  139. Levy MH, Wheelock EF: The role of macrophages in defense against neoplastic disease. Adv Cancer Res 20: 131, 1974.

    Article  PubMed  CAS  Google Scholar 

  140. Evans R, Alexander P: The role of macrophages in tumor immunity, I. Cooperation between macrophages and lymphoid cells in syngeneic tumor immunity. Immunology 23: 615, 1972.

    PubMed  CAS  Google Scholar 

  141. Gelboin HV, Levy HB: Polyinosinic-polycytidylic acid inhibits chemically induced tumo- rigenesis in mouse skin. Science 167: 205, 1970.

    Article  PubMed  CAS  Google Scholar 

  142. Chow DA, Greene MI, Greenberg AH: Macrophage-dependent NK-cell-independent ‘natural’ surveillance of tumors in syngeneic mice. Int J Cancer 23: 788, 1979.

    Article  PubMed  CAS  Google Scholar 

  143. Chow DA, Miller VE, Carlson GA, et al: Natural resistance to tumors is a heterogeneous immunological phenomenon: Evidence for non-NK cell mechanisms. Invas Metas 1: 205, 1981.

    CAS  Google Scholar 

  144. Birbeck MSC, Carter RL: Observations on the ultrastructure of two hamster lymphomas with particular reference to infiltrating macrophages. Int J Cancer 9: 249–257, 1972.

    Article  PubMed  CAS  Google Scholar 

  145. Eccles SA, Alexander P: Macrophage content of tumors in relation to metastatic spread and host immune reaction. Nature 250: 667–669, 1974.

    Article  PubMed  CAS  Google Scholar 

  146. Talmadge JE, Key M, Fidler IJ: Macrophage content of metastatic and nonmetastatic rodent neoplasms. J Immunol 126: 2245–2248, 1981.

    PubMed  CAS  Google Scholar 

  147. Gauci CL: The significance of the macrophage content of human tumors. In: Mathe G (ed) Recent Results in Cancer Research, Vol 56. Berlin, Spinger-Verlag, 1976, pp 122–130.

    Google Scholar 

  148. Wood GW, Gollahon KA: Detection and quantitation of macrophage infiltration into primary human tumors with the use of cell-surface markers. J Natl Cancer Inst 59:1081–1087, 1977.

    Google Scholar 

  149. Alexander P, Eccles SA, Gauci CLL: The significance of macrophages in human and experimental tumors. Ann NY Acad SCi 276: 124–133, 1976.

    Article  PubMed  CAS  Google Scholar 

  150. Brunda MJ, Raffel S: Macrophage processing of antigen for induction of tumor immunity. Cancer Res 37: 1838–1844, 1977.

    PubMed  CAS  Google Scholar 

  151. Shen HH, Talle MA, Goldstein G, Chess L: Functional subsets of human monocytes defined by monoclonal antibodies: a distinct subset of monocytes contains the cells capable of inducing the autogous mixed lymphocyte culture. J Immunol 130: 698–705, 1983.

    PubMed  CAS  Google Scholar 

  152. Berlinger NT, Hilal EY, Oettgen HF, Good RA: Deficient cell-mediated immunity in head and neck cancer patients secondary to autologous suppressive immune cells. Laryngoscope 88: 470–482, 1978.

    Article  PubMed  CAS  Google Scholar 

  153. Balch CM, Dougherty PA, Tilden AB: Excessive prostaglandin E2 production by suppressor monocytes in head and neck cancer patients. Ann Surg 196: 645–650, 1982.

    Article  PubMed  CAS  Google Scholar 

  154. Maca RD, Panje W: Indomethacin sensitive suppressor cell activity in head and neck cancer patients pre and postirradiation therapy. Cancer 50: 484–489, 1982.

    Article  Google Scholar 

  155. Panje WR: Regression of head and neck carcinoma with a prostaglandin-synthesis inhibitor. Arch Otolaryngol 107: 658–663, 1981.

    PubMed  CAS  Google Scholar 

  156. Hirsch B, Johnson JT, Rabin BS, Thearle PB: Immunostimulation of patients with head and neck cancer. Arch Otolaryngol 109: 298–301, 1983.

    PubMed  CAS  Google Scholar 

  157. Wara WM, Wara DW, Phillips TL, Amman AJ: Elevated IgA in carcinoma of the nasopharynx. Cancer 35: 1313–1315, 1975.

    Article  PubMed  CAS  Google Scholar 

  158. Katz AE, Yoo TJ, Harker LA: Serum immunoglobulin A (IgA) levels in carcinoma of the head and neck. Trans Am Acad Ophthalmol Otolaryngol 82: 131–137, 1876.

    Google Scholar 

  159. Wolf GT, Chretien PB, Elias EG, et al: Serum glycoproteins in head and neck squamous carcinoma: correlations with tumor extent, clinical tumor stage and T cell levels during chemotherapy. Am J Surg 138: 489–500, 1979.

    Article  PubMed  CAS  Google Scholar 

  160. Baskies AM, Chretien PB, Maxim PE, et al: Circulating immune complexes correlate with levels of seum immune reactive proteins and clinical tumor stage in head and neck squamous carcinoma. Surg Forum 30: 516–518, 1979.

    PubMed  CAS  Google Scholar 

  161. Wolf GT, Wolfe RA, Chretien PB: Circulating immune complexes in patients with naso-pharyngeal carcinoma (manuscripts submitted to Otolaryngol Head Neck Surg).

    Google Scholar 

  162. Sample WF, Gertner HR, Chretien PB: Inhibition of phytohemagglutinin induced in vitro lymphocyte transformation by serum from patients with carcinoma. J Natl Cancer Inst 46: 1291–1297, 1971.

    PubMed  CAS  Google Scholar 

  163. Sample WF, Gertner HR, Futrell JW, Chretien PB: Suppression of in vitro reactivity of lymphocytes from normal persons by serum from carcinoma patients. Surg Forum 21:116–118, 1970.

    Google Scholar 

  164. Watanabe T, Iglehart JD, Bolognesi DP: Secretroy immune response in patients with oro–pharyngeal carcinoma. Ann Otol Rhinol Laryngol 92: 295–299, 1983.

    PubMed  CAS  Google Scholar 

  165. Brown AM, Lally ET, Frankel A, et al.: The association of the IgA levels of serum and whole saliva with the progression of oral cancer. Cancer 35: 1154–1162, 1975.

    Article  PubMed  CAS  Google Scholar 

  166. Sundar SK, Ablashi DV, Kamaraju LS, et al.: Sera from patients with undifferentiated nasopharyngeal carcinoma contain a factor which abrogates specific Epstein-Barr virus antigen-induced lymphocyte response. Int J Cancer 29: 407–412, 1982.

    Article  PubMed  CAS  Google Scholar 

  167. Veltri RW, Sprinkle PM, Maxim PE, et al: Immune monitoring protocol for patients with carcinoma of the head and neck. Ann Otol 87: 692–700, 1978.

    CAS  Google Scholar 

  168. Hellstrom I, Sjogren HO, Warner GA, et al: Blocking of cell-mediated tumour immunity by sera from patients with growing neoplasms. Int J Cancer 7: 226–237, 1971.

    Article  PubMed  CAS  Google Scholar 

  169. Veltri RW, Radman SM, Sprinkle PM, Quick C: Circulating soluable immune complexes and immunodepression in patients with squamous cell carcinoma of the head and neck. Proc Am Assoc Cancer Res 21: 235, 1980.

    Google Scholar 

  170. Theofilopoulos An, Andrews BS, Urist MM, et al: The nature of immune complexes in human cancer sera. J Immunol 119: 657–663, 1977.

    PubMed  CAS  Google Scholar 

  171. Hellstrom I, Hellstrom KE: Studies on the cellular immunity and its serum mediated inhibitors in Maloney-virus induced tumors. Int J Cancer 4: 587–600, 1969.

    Article  PubMed  CAS  Google Scholar 

  172. Sjogren HO, Hellstrom I, Bansal SC, Hellstrom KE: Suggestive evidence that the blocking antibodies of tumor bearing individuals may be antigen- antibody complex. Proc Natl Acad Sci 68: 1372–1375, 1971.

    Article  PubMed  CAS  Google Scholar 

  173. Mathew GD, Qualtiere LF, Neel HB, Pearson GR: IgA antibody, antibody-dependent cellular cytotoxicity and prognosis in patients with nasopharyngeal carcinoma. Int J Cancer 27: 175–180, 1981.

    Article  PubMed  CAS  Google Scholar 

  174. Wheelock EF, Robinson ML: Endogenous control of the neoplastic process. Lab Invest 48: 120–139, 1983.

    PubMed  CAS  Google Scholar 

  175. Dvorak HF, Orenstein NS, Carvalho AC, et al: Induction of a fibrin-gel investment: an early event in line 10 hepatocarcinoma growth mediated by tumor secreted products. J Immunol 122: 166, 1979.

    PubMed  CAS  Google Scholar 

  176. Sanford BH: An alteration in tumor histocompatability induced by neuraminidase. Transplant 5: 1273–1279, 1967.

    Article  CAS  Google Scholar 

  177. Black PH: Shedding from the cell surface of normal and cancer cells. Adv Cancer Res 32: 75–199, 1980.

    Article  PubMed  CAS  Google Scholar 

  178. Yoshimura S, Tamaoki N, Ueyama Y, Hata J: Plasma protein production by human tumors xenotransplanted in nude mice. Cancer Res 38: 3474–3476, 1978.

    PubMed  CAS  Google Scholar 

  179. Pike MC, Snyderman R: Depression of macrophage function by a factor produced by neoplasms: a mechanism for abrogation of immune surveillance. J Immunol 117:1243–1249, 1976.

    Google Scholar 

  180. Cheung HT, Cantarow WD, Sundharadas G: Characteristics of a low molecular weight factor extracted from mouse tumors that affects in vitro properties of macrophages. Int J Cancer 23: 344–352, 1979.

    Article  PubMed  CAS  Google Scholar 

  181. Wong A, Mankovitz R, Kennedy JC: Immunosuppressive and immunostimulating factors produced by malignant cells in vitro. Int J Cancer 13: 530–542, 1974.

    Article  PubMed  CAS  Google Scholar 

  182. Plescia OJ, Smith AH, Grinwich K: Subversion of immune system by tumor cells and role of prostaglandin. Proc Natl Acad Sci 72: 1848–1851, 1975.

    Article  PubMed  CAS  Google Scholar 

  183. Johnson JT, Rabin BS, Wagner RL: Prostaglandin E2 of the upper aerodigestive tract. (Abstract), Eastern Society, Triological Society, January 1984.

    Google Scholar 

  184. Bennett A, Carter RL, Stamford IF, Tanner NSB: Prostaglandin-like material extracted from squamous carcinoma of the head and neck. Br J Cancer 41: 204–208, 1980.

    Article  PubMed  CAS  Google Scholar 

  185. Wolf GT, Chretien PB: The chemotherapy and immunotherapy of head and neck cancer. In: Suen JY, Myers EN (eds) Cancer of the Head and Neck. New York, Churchill Livingstone, 1981, pp 782–820.

    Google Scholar 

  186. Olivari A, Pradier R, Feierstein J, et al: Cell mediated immunity in head and neck cancer patients. J Surg Oncol 8: 287–290, 1976.

    Article  PubMed  CAS  Google Scholar 

  187. Wanebo HJ: Immunobiology of head and neck cancer: Basic concepts. Head Neck Surg 2: 42 - 55, 1979.

    Article  PubMed  CAS  Google Scholar 

  188. Eilber FR, Morton DL, Ketcham AS: Immunologic abnormalities in head and neck cancer. Am J Surg 128: 534–538, 1974.

    Article  PubMed  CAS  Google Scholar 

  189. Browder JP, Chretien PB: Immune reactivity in head and neck squamous carcinoma and relevance to the design of immunotherapy trials. Sem Oncol 4: 431–439, 1977.

    CAS  Google Scholar 

  190. Stewart CC, Perez CA: Effect of irradiation of immune responses. Radiology 118: 201–210, 1976.

    PubMed  CAS  Google Scholar 

  191. Order SE: The effects of therapeutic irradiation on lymphocytes and immunity. Cancer 39: 737–743, 1977.

    Article  PubMed  CAS  Google Scholar 

  192. Hoppe RT, Fuk ZY, Strober S, Kaplan HS: The long term effects of radiation on T and B lymphocytes in the peripheral blood after regional irradiation. Cancer 40: 2071–2078, 1977.

    Article  PubMed  CAS  Google Scholar 

  193. Rabou M, Heise ER, Kucera LS, et al: Effects of irradiation on lymphocyte subpopulations. In: Dubois JB, Serrou B, Rosenfeld C (eds) Immunologic Effects of Radiation Therapy. New York, Raven Press, 1981, pp 321–328.

    Google Scholar 

  194. Wasserman J, Baral E, Biberfeld G, et al: Effects of in vitro irradiation on lymphocyte subpopulations and cytoxicity. In: Dubois JB, Serrou B, Rosenfeld C (eds) Immunologic Effects of Radiation Therapy. New York, Raven Press, 1981, pp 123–135.

    Google Scholar 

  195. Baskies AM, Chretien PB, Baer SB: Radiation therapy: its effects on immune reactivity. Prog Clin Cancer 8: 215–226, 1982.

    PubMed  CAS  Google Scholar 

  196. Cheema AR, Hersh EM: Patient survival after chemotherapy and its relationship to in vitro lymphocyte blastogenesis. Cancer 28: 851–855, 1971.

    Article  PubMed  CAS  Google Scholar 

  197. Colmerauer ME, Koziol JA, Pilch YH: Enhancement of metastasis development by BCG immunotherapy. J Surg Oncol 15: 235–241, 1980.

    Article  PubMed  CAS  Google Scholar 

  198. Mathe G, Florentin I, Olsson L, et al: Pharmacologic factors and manipulation of immunity systemic adjuvants in cancer therapy. Cancer Treatment Rep 62: 1613, 1978.

    CAS  Google Scholar 

  199. Blomberg BME, Glerum J, Croles JJ, et al: Harmful effects of I.V. Corynebacterium par- vum given at the same time as cyclophosphamide in patients with squamous-cell carcinoma of the bronchus. Br J Cancer 41: 609–617, 1980.

    Article  Google Scholar 

  200. Mathe G, Amiel JL, Schwarzenberg L, et al: Followup of the first (1962) pilot study on active immunotherapy of acute lymphoid leukemia: A critical discussion. Biomed 24: 29, 1977.

    Google Scholar 

  201. Alberts DS: Adjuvant immunotherapy with BCG of advanced ovarian cancer: A preliminary report. In: Salmon SI, Jones SE (eds) Adjuvant Therapy of Cancer. Amsterdam, Elsevier/North-Holland Biomedical Press, 1977, p 327.

    Google Scholar 

  202. McKneally MF, Maver C, Kause HW: Regional immunotherapy of lung cancer with intrapleural BCG. Lancet 1: 337, 1976.

    Google Scholar 

  203. Morton DL, Eilber FR, Holmes EC: Present status of BCG immunotherapy of malignant melanoma. Cancer Immunol Immunother 1: 93–98, 1976.

    Article  Google Scholar 

  204. Veronesi U, Adamus J, Aubert C, et al: A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma. New Engl J Med 307: 913–916, 1982.

    Article  PubMed  CAS  Google Scholar 

  205. Mountain CF, Gail MH: Surgical adjuvant intrapleural BCG treatment for Stage I non–small cell lung cancer. J Thor Cardiovasc Surg 82: 649–657, 1981.

    Google Scholar 

  206. Beuchler M, Mukheiji B, Chasin W, Nathanson L: High dose methotrexate with and without BCG therapy in advanced head and neck malignancy. Cancer 43: 1095, 1979.

    Article  Google Scholar 

  207. Papac R, Minor DR, Rudnick S, et al: Controlled trial of methotrexate and bacillus Cal- mette-Guerin therapy for advanced head and neck cancer. Cancer Res 38: 3150, 1978.

    PubMed  CAS  Google Scholar 

  208. Cunningham TJ, Antemann R, Paonessa D, et al: Adjuvant immuno and/or chemotherapy with neuraminidase–treated autogenous tumor vaccine and bacillus Calmette–Guerin for head and neck cancer. Ann NY Acad Sci 277: 339, 1976.

    Article  PubMed  CAS  Google Scholar 

  209. Taylor SG, Sisson GA, Bytell DE: Adjuvant chemo immunotherapy of head and neck cancer. Recent Results Cancer Res 68: 297, 1979.

    Google Scholar 

  210. Richman SP, Livingston RB, Gutterman JU, et al: Chemotherapy versus chemo immunotherapy of head and neck cancer: Reports of a randomized study. Cancer Treat Rep 60: 535–537, 1976.

    PubMed  CAS  Google Scholar 

  211. Amiel JL, Sancho-Garnier H, Vandenbrouck G, et al: First results of a randomized trial on immunotherapy of head and neck tumors. Recent Results Cancer Res 68: 318, 1979.

    Google Scholar 

  212. Beatty DJ, Terz JJ, Brown PW, et al: Adjuvant intralesional and systemic Corynebacter- ium parvum immunotherapy for surgically treated head and neck cancer. Surg Forum 31: 155–156, 1980.

    Google Scholar 

  213. Vogl SE, Schoenfeld DA, Kaplan BH, et al: Methotrexate alone or with regional subcutaneous Corynebaeterium parvum in the treatment of recurrent and metastatic squamous cancer of the head and neck. Cancer 50: 2295–2300, 1982.

    Article  PubMed  CAS  Google Scholar 

  214. Cheng VST, Suit HD, Wang CC, et al: Clinical trial of Cornybacterium parvum (intra- lymph node and intravenous) and radiation therapy in the treatment of head and neck carcinoma. Cancer 49: 239–244, 1982.

    Article  PubMed  CAS  Google Scholar 

  215. Szpirglas H, Chastang C, Bertrand JC: Adjuvant treatment of tongue and floor of the mouth cancers. Recent Results cancer Res 68: 309–315, 1979.

    Google Scholar 

  216. Cruse JP, Lewin MR, Clark CG: Corynebaeterium parvum enhances colonic cancer in dimethydrazine-treated rats. Br J Cancer 37: 639–643, 1978.

    Article  PubMed  CAS  Google Scholar 

  217. Fisher B, Gebhardt M, Linta J, Saffer E: Comparison of the inhibition of tumor growth following local or systemic administration of Corynebaeterium parvum or other immunos- timulating agents with or without cyclophosphamide. Cancer Res 38: 2679–2687, 1978.

    PubMed  CAS  Google Scholar 

  218. Isaacs A, Lindenmann J: Virus interference: The interferon. Proc Royal Soc 147: 258–267, 1957.

    Article  CAS  Google Scholar 

  219. Sonnenfeld G, Merigan TC: A regulatory role for interferon in immunity. Ann NY Acad Sci 332: 345–355, 1979.

    Article  PubMed  CAS  Google Scholar 

  220. Pang RHL, Yip YK, Vilcek J: Immune interferon induction by a monoclonal antibody specific for human T cells. Cellular Immunol 64: 304–311, 1981.

    Article  CAS  Google Scholar 

  221. Friedman RM: Interferons and cancer. J Natl Cancer Inst 60: 1191–1194, 1978.

    PubMed  CAS  Google Scholar 

  222. Gutterman JU, Blumenschein GR, Alexanian R, et al: Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma and malignant lymphoma. Ann Intern Med 93: 399–406, 1980.

    PubMed  CAS  Google Scholar 

  223. Horning SJ, Levine JF, Miller RA, et al: Clinical and immunologic effects of recombinant leukocyte A interferon in eight patients with advanced cancer. J Am Med Assoc 247: 1718–1722, 1982.

    Article  CAS  Google Scholar 

  224. Krusie J, Kirhmajer V, Knezevic M, et al: Influence of human leukocyte interferon on squamous cell carcinoma of uterine cervix: clinical, histological and histochemical observations. J Cancer Res Clin Oncol 101: 309–315, 1981.

    Article  Google Scholar 

  225. Connors JM, Andiman WA, Merigan TC, et al: Treatment of nasopharyngeal carcinoma with interferon: Epstein-Barr virus serology and clinical results of a pilot study. Proc Am Soc Clin Oncol 1: 198, 1982.

    Google Scholar 

  226. Padovan I, Brodarec I, Ikic D, et al.: Effect of interferon in therapy of skin and head and neck tumors. J Cancer Res Clin Oncol 100: 295–310, 1981.

    Article  PubMed  CAS  Google Scholar 

  227. Krown SE, Real FX, Cunningham-Rundles S, et al.: Recombinant leukocyte A interferon in homosexual men with Kaposi’s sarcoma. N Engl J Med 308: 1071–1074, 1983.

    Article  PubMed  CAS  Google Scholar 

  228. Einhorn S, Ahre A, Blomgren H, et al.: Interferon and natural killer activity in multiple myeloma. Lack of correlation between interferon-induced enhancement of natural killer activity and clinical response to human interferon-alpha. Int J Cancer 30: 167–172, 1982.

    Article  PubMed  CAS  Google Scholar 

  229. Schafer LA, Goldstein AL, Gutterman JN, Hersh EM: In vitro and in vivo studies with thymosin in cancer patients. Ann NY Acad Sci 277: 609–612, 1976.

    Article  PubMed  CAS  Google Scholar 

  230. Schulof RS, Goldstein AL: Clinical application of thymosin and other thymic hormones. Recent Adv Clin Immunol 3: 243–286, 1983.

    Google Scholar 

  231. Kenady DE, Chretien PB, Potvin C, Simon RM: Thymosin reconstitution of T cell deficits in vitro in cancer patients. Cancer 39: 575–580, 1977.

    Article  PubMed  CAS  Google Scholar 

  232. Wolf GT, Kerney SE, Chretien PB: Improvement of impaired leukocyte migration inhibition by thymosin in patients with head and neck squamous carcinoma. Am J Surg 140: 531–537, 1980.

    Article  PubMed  CAS  Google Scholar 

  233. Constanzi JJ, Gaghano RG, Delaney R, et al.: The effect of thymosin on patients with disseminated malignancies. Cancer 40: 14–19, 1977.

    Article  Google Scholar 

  234. Lipson SD, Chretien PB, Makuch R, et al: Thymosin immunotherapy in patients with small cell carcinoma of the lung. Cancer 43: 863–870, 1979.

    Article  PubMed  CAS  Google Scholar 

  235. Schulof RS, Lloyd M, Cox J, Goldstein AL: Synthetic thymosin alpha 1 following mediastinal irradiation: a randomized trial in patients with locally advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 2: 185, 1983.

    Google Scholar 

  236. Wara WM, Neely MH, Amann AJ, Wara DW: Biologic modifications of immunologic parameters in head and neck cancer patients with thymosin fraction V. In: Goldstein AL, Chirigos MA (eds) Lymphokines and Thymic Hormones: Their Potential Utilization in Cancer Therapeutics. New York, Raven Press, 1981, pp 257–262.

    Google Scholar 

  237. Fletcher GH: Place of radiation modulation in the management of head and neck cancer. Sem Oncol 4: 375–385, 1977.

    CAS  Google Scholar 

  238. Jesse RH, Lindberg RD: The efficacy of combining radiation therapy with a surgical procedure in patients with cervical metastasis from squamous cancer of the oropharynx and hypopharynx. Cancer 35: 1163–1166, 1975.

    Article  PubMed  CAS  Google Scholar 

  239. Schuller DE, McGuirt WF, Krause CF, et al.: Increased survival with surgery alone versus combined therapy. Laryngoscope 89: 582–594, 1979.

    Article  PubMed  CAS  Google Scholar 

  240. Strong MS, Vaughn CW, Kayna NL, et al.: A randomized trial of preoperative radiotherapy in cancer of the oropharynx and hypopharynx. Am J Surg 136: 494–500, 1978.

    Article  PubMed  CAS  Google Scholar 

  241. Baker D, Elkan D, Lim M, et al.: Does local x-irradiation of a tumor increase the incidence of metastases? Cancer 48: 2394–2398, 1981.

    Article  PubMed  CAS  Google Scholar 

  242. Lundy J, Lovett EJ, Wolinsky SM, Conran P: Immune impairmant and metastatic tumor growth. Cancer 43: 945–951, 1979.

    Article  PubMed  CAS  Google Scholar 

  243. Serrou B, Rosenfeld C, Caraux J, et al.: Thymosin modulation of suppressor function in mice and man. Ann NY Acad Sci 332: 95–100, 1979.

    Article  PubMed  CAS  Google Scholar 

  244. Klein AS, Shoham J: Effect of the thymic factor, thymostimulin (TP-1) on the survival rate of tumor–bearing mice. Cancer Res 41: 3217–3221, 1981.

    PubMed  CAS  Google Scholar 

  245. Cupissol D, Touraine JL, Serrou B: Ability of lymphocytes treated with thymic factor to decrease lung metastases in tumor-bearing mice. Thymus 3: 9–16, 1981.

    PubMed  CAS  Google Scholar 

  246. Goldstein G: Made of action of levamisole. J Rheumatol 5: 143, 1978.

    Google Scholar 

  247. Amery WK: Final results of a multicenter placebo-controlled levamisole study of resectable lung cancer. Cancer Treat Rep 62: 1677–1680, 1978.

    PubMed  CAS  Google Scholar 

  248. Rojas AF, Feierstein JH, Glait HM, Olivari AJ: Levamisole action in breast cancer Stage III. In: Terry WD, Windhorst D (eds) Immunotherapy of Cancer: Present Status of Trials in Man. New York, Raven Press, 1977, p635.

    Google Scholar 

  249. Mussche RA, Kluyskens P: Prognosis of primarily treated localized laryngeal carcinoma ameliorated through levamisole treatment. Oncology 35: 329–335, 1980.

    Article  Google Scholar 

  250. Olivari AJ, Glait HM, Guardo A, et al.: Levamisole in squamous cell carcinoma of the head and neck. Cancer Treat Rep 63: 983, 1979.

    PubMed  CAS  Google Scholar 

  251. Olkowski Z, McLaren J, Skeen M: Effects of combined immunotherapy with levamisole and bacillus Calmette-Guerin on immune-competence of patients with squamous cell carcinoma of the cervix, head and neck and lung undergoing radiation therapy. Cancer Treat Rep 62: 1651, 1978.

    PubMed  CAS  Google Scholar 

  252. Wanebo HJ, Hilal EY, Pinsky CM, et al.: Randomized trial of levamisole in patients with squamous cancer of the head and neck: A preliminary report. Cancer Treat Rep 62: 1663–1669, 1978.

    PubMed  CAS  Google Scholar 

  253. Bier J, Rapp HJ, Borsos T, et al.: Randomized clinical study on intratumoral BCG-cell wall preparation (CWP) therapy in patients with squamous cell carcinoma on he head and neck region. Cancer Immunol Immunother 12: 71–79, 1981.

    Article  Google Scholar 

  254. Goldenberg GJ, Brandes LJ: In vivo and in vitro studies of immunotherapy of nasopharyngeal carcinoma with transfer factor. Cancer Res 36: 720–723, 1976.

    PubMed  CAS  Google Scholar 

  255. Nair PNM, Gangal SG, Agashe SS, Rao RS: Immunologic studies on human oral cancer. Ind J Cancer 13: 64–69, 1976.

    CAS  Google Scholar 

Download references

Authors
  1. Gregory T. Wolf
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Otolaryngology Head and Neck Surgery Division, University of Michigan, Ann Arbor, Michigan, USA

    Gregory T. Wolf

Rights and permissions

Reprints and permissions

Copyright information

© 1984 Martinus Nijhoff Publishers, Boston

About this chapter

Cite this chapter

Wolf, G.T. (1984). Tumor immunology, immune surveillance and immunotherapy of head and neck squamous carcinoma. In: Wolf, G.T. (eds) Head and Neck Oncology. Cancer Treatment and Research, vol 22. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-3816-1_16

Download citation

  • DOI: https://doi.org/10.1007/978-1-4613-3816-1_16

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-3818-5

  • Online ISBN: 978-1-4613-3816-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation